Appointments, Market Activity, Regulatory Approvals, and Rights Acquisition - Research Reports on Nike, Morgan Stanley, Regeneron, Zimmer and Jazz

NEW YORK, August 21, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Nike, Inc. (NYSE: NKE), Morgan Stanley (NYSE: MS), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Zimmer Holdings, Inc. (NYSE: ZMH) and Jazz Pharmaceuticals plc (NASDAQ: JAZZ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5880-100free.

--
Nike, Inc. Research Reports
On August 15, 2014, Nike, Inc. (Nike) announced two management appointments in two important areas of its global business - Retail (Direct to Consumer) and Women's. The Company said that it has appointed Heidi O'Neill to the newly created role of Vice President, General Manager of Nike Stores, responsible for all aspects of Nike's retail presence worldwide, including oversight of Nike-branded partner stores. Nike also appointed Amy Montagne as Vice President, General Manager of Women's division, responsible for expanding Nike's brand position with women. "NIKE innovates to deepen our connections with consumers worldwide. These two appointments demonstrate our commitment to investing in our retail experience and our women's business - two of our most strategic growth opportunities. We're delighted to elevate two seasoned NIKE leaders in these important roles," said Trevor Edwards, President, Nike Brand. The full research reports on Nike are available to download free of charge at:

http://www.analystsreview.com/Aug-21-2014/NKE/report.pdf

--
Morgan Stanley Research Reports
On August 18, 2014, the stock of Morgan Stanley gained 1.21% to end the trading session at $32.61. During the session, the stock opened at $32.47, and fluctuated in the range of $32.39 - $32.74. Over the last one month, the stock of Morgan Stanley lost 0.09%, compared to the S&P 500 Index which declined by 0.33% during the same period. The full research reports on Morgan Stanley are available to download free of charge at:

http://www.analystsreview.com/Aug-21-2014/MS/report.pdf

--
Regeneron Pharmaceuticals, Inc. Research Reports
On August 11, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron) announced that EYLEA® (aflibercept) Injection has received the approval of the European Commission for the treatment of visual impairment due to Diabetic Macular Edema (DME). Bayer Healthcare, which has collaborated with Regeneron on the global development of EYLEA, plans to launch the injection in DME in the EU this quarter. "We are pleased that EYLEA is now approved in both the U.S. and the EU for three important ophthalmic indications," said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. While Regeneron maintains exclusive rights to EYLEA in the U.S., Bayer HealthCare has the rights to market it outside the U.S. The Company also informed that regulatory submissions have been made in Japan, Asia Pacific, and Latin America for the treatment of DME. The full research reports on Regeneron are available to download free of charge at:

http://www.analystsreview.com/Aug-21-2014/REGN/report.pdf

--
Zimmer Holdings, Inc. Research Reports
On August 18, 2014, the stock of Zimmer Holdings, Inc. (Zimmer) gained 1.88% to end the trading session at $99.31. During the session, the stock opened at $97.88, which was also its low of the day, and touched an intra-day high of $99.32. Over the last one month, the stock of Zimmer has declined by 3.06%, compared to the Dow Jones Industrial Average which declined 1.53% during the same period. The full research reports on Zimmer are available to download free of charge at:

http://www.analystsreview.com/Aug-21-2014/ZMH/report.pdf

--
Jazz Pharmaceuticals plc Research Reports
On August 5, 2014, Jazz Pharmaceuticals plc (Jazz) announced that it closed the acquisition of rights to defibrotide in the U.S. and all other countries in the Americas from Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau), and now owns worldwide rights to defibrotide. The Company stated that defibrotide is a novel product that is marketed by it in the EU under the name Defitelio® for the treatment of severe hepatic veno-occlusive disease (VOD) in patients over one month of age undergoing hematopoietic stem cell transplantation (HSCT) therapy. Jazz has acquired the rights through a wholly-owned subsidiary for an upfront payment of $75 million plus potential milestone payments of $25 million upon the acceptance for filing by the U.S. Food and Drug Administration (FDA) of the first New Drug Application (NDA) for defibrotide for VOD and up to an additional $150 million based on the timing of potential FDA approval of defibrotide for VOD. The full research reports on Jazz are available to download free of charge at:

http://www.analystsreview.com/Aug-21-2014/JAZZ/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review